It is important that the medical profession play a significant role in critically evaluating the
use of diagnostic procedures and therapies as they are introduced and tested in the …

The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

The ACC/AHA Task Force on Practice Guidelines was formed to make recommendations
regarding the diagnosis and treatment of patients with known or suspected cardiovascular …

Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …

2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the
Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction …

Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its
morbidity and mortality. Because little advance has been made in outcomes following ST …

For new or updated text, view the 2011 Focused Update. Text supporting unchanged
recommendations has not been updated. The ACC/AHA Task Force on Practice Guidelines …

Ticagrelor (AZD6140) is the first reversibly binding oral P2Y12 receptor antagonist that
blocks ADP‐induced platelet aggregation. Unlike thienopyridines, which irreversibly bind to …

Aims We sought to compare the results obtained from six major platelet function tests in the
assessment of the prevalence of aspirin resistance in patients with stable coronary artery …

This article about currently available antiplatelet drugs is part of the Antithrombotic and
Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical …